Twin Health AI Program Lowers A1C, Cuts GLP‑1 Use in 12‑Month Trial
Twin Health's AI-enabled lifestyle program produced clinically meaningful reductions in blood glucose and medication dependence during a 12-month randomized study, with 71% of users reaching an A1C under 6.5% while using fewer drugs compared with 2% in the control arm. The trial enrolled 150 adults and reported average weight loss of 8.6% for the intervention group versus 4.6% for controls, and a marked drop in GLP‑1 prescriptions among program users.
The platform combines meal logging with an AI model that forecasts an individual's glycemic response and then issues real‑time, personalized suggestions for portioning, food pairing, or post‑meal activity. Recommendations are optional; members may follow them or keep existing routines, while the system adapts to declared preferences and behavioral patterns over time. Human coaching remains available as an adjunct for clinical questions or motivational support.
Clinicians at the Cleveland Clinic ran the randomized comparison, allocating 100 participants to the Twin program and 50 to usual care. The cohort averaged 58 years of age, presented with obesity, and had a mean baseline A1C around 7.2%. The primary objective focused on achieving A1C under 6.5% alongside reduced medication burden.
Beyond aggregated outcomes, the study documented a sharp reduction in GLP‑1 agent use: program participants saw rates fall from 41% at baseline to 6% after 12 months, while control participants moved from 52% to 63%. Those shifts indicate the intervention can substitute, in part, for pharmacologic intensification for many patients. Secondary signals included improved activity levels and biometric trends that reinforced lifestyle impact and supported medication de‑escalation in some cases.
The findings were reported in a peer‑reviewed forum and strengthen the evidence that algorithmic personalization paired with behavioral coaching can change metabolic trajectories. For payers and health systems, the data suggest potential to lower prescription spending on high-cost incretin drugs while achieving guideline-level glycemic targets. For clinicians, the results offer a validated nonpharmacologic pathway to consider before escalating medication regimens.
Operationally, the model's data inputs are lightweight—meal logs and user feedback—making deployment feasible across remote care environments. Semantic adjacencies include continuous glucose monitoring, GLP‑1 receptor agonists, and digital therapeutics, all relevant to integrating this program into broader chronic disease management. Real‑world implementation will hinge on patient engagement, interoperability with electronic medical records, and reimbursement models that reward medication reduction and outcome improvement.
Read Our Expert Analysis
Create an account or login for free to unlock our expert analysis and key takeaways for this development.
By continuing, you agree to receive marketing communications and our weekly newsletter. You can opt-out at any time.
Recommended for you
GLP‑1 drugs linked to lower addiction risk in large VA analysis
A VA cohort study of roughly 600,000 patients finds GLP‑1 therapy associates with a 15–20% drop in substance misuse and a 25–50% fall in severe outcomes among those with prior disorder. Early signals are promising but likely heterogeneous by agent and patient biology — trials should compare GLP‑1 receptor agonists and dual‑agonists (eg, tirzepatide) and stratify by biomarkers, because response patterns observed in obesity care suggest variable neurobehavioral effects across individuals and drugs.
Why GLP‑1 Medicines Help Many but Not All — and How obesity care could become personalized
GLP‑1 and related injectable therapies have produced dramatic weight loss for a substantial subset of patients, but responsiveness varies widely because obesity is biologically diverse. Advances in genetic profiling, hormone receptor science and microbiome analysis are pointing toward tailored treatment algorithms that may pair drugs, older medications, and behavioral interventions to improve outcomes.
Conagra, Nestle Pivot Packaged Meals Toward GLP-1 Users
Large food makers are labeling frozen meals as GLP-1 Friendly , launching a new shelf category aimed at users of drugs like Wegovy and Zepbound ; Conagra has applied the check-mark to 26 SKUs and plans to add 6 more. The tactic taps a growing user base (roughly 12% of U.S. adults today and projected to approach 30 million users by 2030 as oral formulations and possible Medicare coverage lower barriers) but also raises nutrition, regulatory and retailer-assortment questions.
Food & Beverage Industry Braces as GLP-1 Use Rewires Demand
Rising use of GLP-1 therapies — turbocharged by new oral formulations and looming Medicare coverage — is already cutting caloric intake and buyer spend, putting $30B–$55B of annual sales at risk by 2030. However, clinical heterogeneity, adherence cycles, and near-term manufacturing constraints introduce meaningful uncertainty about the pace and permanence of demand shifts, giving fast-moving food companies only a limited window to reformulate, downsize portions, and chase protein-and-fiber demand or cede share to agile challengers.
Mehmet Oz Proposes AI Avatars to Address Rural Health Shortages
CMS chief Mehmet Oz is pitching AI avatars and automated diagnostics as part of a proposed $50 billion rural modernization plan to expand clinician reach and cut paperwork, while experts warn the approach raises clinical safety, privacy, governance and digital‑equity concerns that must be resolved before scale‑up.
Ant Group Redirects Growth Strategy Toward AI-Powered Healthcare
Ant Group has repositioned its corporate focus to develop AI-driven health services, elevating its health division to parity with core payment and lending units. The pivot leverages the firm's data and consumer footprint to pursue opportunities in a market estimated around $69 billion, but it faces regulatory hurdles and steep commercialization challenges.
Lotus Health Raises $35M to Scale an AI-Led Primary Care Service in the United States
Lotus Health closed a $35M Series A to expand a no-cost, AI-first virtual primary care practice that uses automated clinical intake and clinician sign-off to issue orders, prescriptions and referrals. Industry blueprints for AI-driven care emphasize a governed execution layer — provenance, observability, rollback and payment-readiness — all of which will be crucial to validating Lotus’s hybrid model and unlocking reimbursement and scale.
Eli Lilly Leads Price War in US Weight‑Loss Drug Market
Competition among GLP‑1 makers has forced steep list‑price cuts, expanded retail and direct sales channels, and prompted manufacturers — led by Eli Lilly — to position new oral launches around an anticipated Medicare coverage change that could set a roughly $50/month copay and expand the Medicare addressable market. Lilly’s simultaneous push (including a $3.5bn manufacturing investment) and the prospect of low‑cost branded generics create a near‑term relief story for some patients but a complex, timing‑dependent commercial and payer‑economics challenge.